• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Synlogic Inc.

    4/18/24 11:18:42 AM ET
    $SYBX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SYBX alert in real time by email
    SC 13G 1 sc13g09076039_04182024.htm THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. )1

     

    Synlogic, Inc.

     (Name of Issuer)

    Common Stock, par value $0.001 per share

     (Title of Class of Securities)

    87166L209

     (CUSIP Number)

    April 10, 2024

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 87166L209

     

      1   NAME OF REPORTING PERSON  
             
            Bradley L. Radoff  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☐
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            USA  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         629,211  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              629,211  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            629,211  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            5.4%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    2

    CUSIP No. 87166L209

    Item 1(a).Name of Issuer:

     

    Synlogic, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    301 Binney Street, Suite 402

    Cambridge, Massachusetts 02142

     

    Item 2(a).Name of Person Filing:

     

    This statement is filed by Bradley L. Radoff.

     

    Item 2(b).Address of Principal Business Office or, if None, Residence:

     

    The address of the principal office of Mr. Radoff is 2727 Kirby Drive, Unit 29L, Houston, Texas 77098.

     

    Item 2(c).Citizenship:

     

    Mr. Radoff is a citizen of the United States of America.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.001 per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    87166L209

     

    3

    CUSIP No. 87166L209

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J).
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership.

     

    (a)Amount beneficially owned:

     

    As of the date hereof, Mr. Radoff directly beneficially owns 629,211 Shares.

     

    (b)Percent of class:

     

    The following percentage is based on 11,646,977 Shares outstanding as of March 12, 2024, which is the total number of Shares outstanding as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 19, 2024.

     

    As of the date hereof, Mr. Radoff beneficially owns approximately 5.4% of the outstanding Shares.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Cover Pages Items 5-9.

     

    4

    CUSIP No. 87166L209

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Cover Pages Items 5-9.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below the undersigned certifies that, to the best of his knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    5

    CUSIP No. 87166L209

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: April 18, 2024

     

     

    /s/ Bradley L. Radoff

      Bradley L. Radoff

     

    6

     

    Get the next $SYBX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYBX

    DatePrice TargetRatingAnalyst
    11/24/2021$7.00Perform → Outperform
    Oppenheimer
    11/24/2021Perform → Outperform
    Oppenheimer
    11/11/2021$15.00 → $11.00Outperform
    SVB Leerink
    10/13/2021$9.00 → $7.00Buy
    HC Wainwright & Co.
    9/20/2021$7.00 → $9.00Overweight
    Piper Sandler
    6/28/2021$13.00 → $9.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SYBX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synlogic Inc.

      10-Q - SYNLOGIC, INC. (0001527599) (Filer)

      5/8/25 4:30:30 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Synlogic Inc.

      10-K/A - SYNLOGIC, INC. (0001527599) (Filer)

      4/30/25 11:57:58 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synlogic Inc.

      10-K - SYNLOGIC, INC. (0001527599) (Filer)

      3/6/25 4:47:33 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synlogic Reports Third Quarter 2024 Financial Results

      WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the third quarter 2024 and provided a corporate update. As previously announced, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Synlogic Board of Di

      11/12/24 4:35:09 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports Second Quarter 2024 Financial Results

      WINCHESTER, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the second quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetab

      8/8/24 7:00:52 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Reports First Quarter 2024 Financial Results

      CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported financial results for the first quarter 2024 and provided a corporate update. In March 2024, the Company retained Lucid Capital Markets, LLC to act as its financial advisor to explore and evaluate strategic options for maximizing shareholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involving the Company. The Board has not set a timetable fo

      5/14/24 7:00:28 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Synlogic upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Synlogic from Perform to Outperform and set a new price target of $7.00

      11/24/21 7:28:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic upgraded by Oppenheimer

      Oppenheimer upgraded Synlogic from Perform to Outperform

      11/24/21 4:55:59 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Synlogic with a new price target

      SVB Leerink reiterated coverage of Synlogic with a rating of Outperform and set a new price target of $11.00 from $15.00 previously

      11/11/21 5:14:48 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Shea Richard P was granted 15,000 shares, increasing direct ownership by 2,964% to 15,506 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:46:11 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Flynn James P was granted 15,000 shares (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/29/25 4:43:44 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Dooley Mary Beth sold $173 worth of shares (144 units at $1.20), decreasing direct ownership by 1% to 12,901 units (SEC Form 4)

      4 - SYNLOGIC, INC. (0001527599) (Issuer)

      4/3/25 4:30:42 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Synlogic Inc.

      SC 13G/A - SYNLOGIC, INC. (0001527599) (Subject)

      11/14/24 4:40:57 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Synlogic Inc. (Amendment)

      SC 13D/A - SYNLOGIC, INC. (0001527599) (Subject)

      5/16/24 7:44:32 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Synlogic Inc.

      SC 13G - SYNLOGIC, INC. (0001527599) (Subject)

      4/18/24 11:18:42 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SYBX
    Financials

    Live finance-specific insights

    See more

    $SYBX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synlogic Adopts Limited Duration Stockholders Rights Plan

      CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today announced that its Board of Directors (the "Board") has approved the adoption of a limited duration shareholder rights plan (the "Rights Plan") and authorized a dividend distribution of one right ("Right") for each outstanding share of common stock. The dividend distribution will be made on March 1, 2024, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on February 20, 2025. The Company also

      2/20/24 12:15:26 PM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Achievement of Proof of Concept for SYNB8802 in Enteric Hyperoxaluria Based on Urinary Oxalate Lowering in Phase 1b Study

      Results include -38% reduction in urinary oxalate compared to placebo in Roux-en-Y gastric bypass patients Favorable safety and tolerability, with frequency and severity of adverse events similar across placebo and active arms Synlogic to host webcast today at 8:30 am. ET with Dr. Kyle Wood, Associate Professor, Urology,​ University of Alabama ​at Birmingham  CAMBRIDGE, Mass., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced that SYNB8802 has demonstrated proof of concept through clinically significant

      12/15/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3

      Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of activity across all assessed endpoints Company confirms SYNB1934 as candidate for Phase 3 initiation expected in H1 2023 Synlogic to Host Webcast Today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced positive top-line data from the Phase 2 Synpheny-1 study in phenylketonuri

      10/18/22 6:59:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development

      Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development. Dr. Hubbert has an extensive background in cell therapy research and venture investment across a broad range of therapeutic modalities and development stages, and has a proven ability to combine deep scientific expertise and business development acumen to identify innovative opportunities to drive both returns and impact. Dr. Hubbert previously served as Partner and Head of Gates Foundation Venture

      4/1/24 8:00:00 AM ET
      $LCTX
      $SYBX
      $VIR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Synlogic Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Updates

      – Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934 for PKU and SYNB1353 for homocystinuria (HCU) – - Platform presentation and two poster presentations at SIMD Annual Meeting – – $77.6 million in cash, cash equivalents and marketable securities support projected runway into second half of 2024 –    CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the fourth quarter and full year ending December 31, 2022 and provided a business update. "

      3/29/23 6:40:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synlogic Announces Appointment of Dr. Dave Hava as Head of Research and Development

      CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (NASDAQ:SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its proprietary approach to synthetic biology, today announced the appointment of Dr. Dave Hava to Head of Research and Development effective January 1, 2023. "Developing a new therapeutic modality requires seamless integration of research and clinical development so that learnings from the clinic can be immediately applied to earlier programs," said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. "Since joining the company, Dave has demonstrated the attributes required

      1/3/23 6:58:00 AM ET
      $SYBX
      Biotechnology: Pharmaceutical Preparations
      Health Care